Natera, Inc. (NTRA) Stock Price & Analysis

Natera, Inc. (NTRA) rose 4.38% to USD 222.82 as of June 10, 2026 at 03:04 UTC, according to Nexqual real-time market data.

NTRA last closed at USD 213.47; the session ranged USD 211.25–222.98 on volume of 1,107,259 shares. Market capitalization is $31.91B, with a 52-week range of USD 131.81–256.36 (NMS). Source: Nexqual, June 10, 2026 at 03:04 UTC.

Key Statistics (as of June 10, 2026 at 03:04 UTC)

Technical Analysis (NTRA)

Nexqual's technical model rates NTRA "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 03:04 UTC.

Analyst Ratings (NTRA)

Wall Street analysts rate NTRA "Strong Buy" based on 19 analysts, with a mean price target of USD 259.26 (range USD 193–300), per Nexqual as of June 10, 2026 at 03:04 UTC.

Earnings (NTRA)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 03:04 UTC.

Financials & Fundamentals (NTRA)

Source: Nexqual, June 10, 2026 at 03:04 UTC.

Financial Health Score (NTRA)

Nexqual rates Natera, Inc.'s overall financial health "Solid" across five dimensions, as of June 10, 2026 at 03:04 UTC.

Ownership (NTRA)

Source: Nexqual, June 10, 2026 at 03:04 UTC.

Leadership (NTRA)

Natera, Inc. is led by Steven Leonard Chapman (age 46), CEO & Director, per Nexqual as of June 10, 2026 at 03:04 UTC.

Major Backers & Investors (NTRA)

Notable institutional backers of Natera, Inc. include JPMorgan, Price (T.Rowe) Associates Inc, Wellington Management, according to Nexqual as of June 10, 2026 at 03:04 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 03:04 UTC.

From Natera, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)

Key Strengths & Strategy (as disclosed to the SEC)

• Our approach combines proprietary molecular biology and computational techniques to measure genomic variations in tiny amounts of DNA, as small as a single cell.
• To make sense of the resulting deep and rich set of biological data and deliver a test result, we have developed computationally intensive algorithms that combine the data generated by mmPCR with our internal databases and the vast and growing sources of publicly available genomic information to build highly detailed models of the genomic regions of interest.
• Our technologies allow us to achieve a high signal-to-noise ratio when detecting fragments of DNA at frequencies as low as a single copy, which allows us to deliver tests with a high degree of specificity and sensitivity.
• We believe our approach represents a fundamental advance in molecular biology.

Partnerships

• We are continuing to generate data, building evidence of the clinical validity and utility of the test across multiple cancer types and in collaboration with leading universities and cancer centers, NIH's National Cancer Institute, or NCI, non-profit cancer research groups, and pharmaceutical companies.
• Our original clinical validation study for Prospera Kidney, conducted in collaboration with the University of California, San Francisco, a recognized leader in transplantation care, and published in the Journal of Clinical Medicine, demonstrated 89% sensitivity in detecting active rejection, with an AUC of 0.87 and NPV of 95%, based on a cutoff of 1% dd-cfDNA.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:04 UTC. This page is informational and not investment advice.